QUICK BUY ALERT: ILLUMINA (ILMN)

As the market tumbles this Tuesday, we’ve found it a great opportunity to add another stock to our site’s portfolio. This time, it’s Illumina (ILMN).

Illumina is a genetic research play. The company manufactures and sells systems and products that analyze genetic functions. This means that they provide the tools necessary for other companies and organizations to perform genetic research, which can be done for various reasons. This sort of technology can assist medically in the form of understanding and diagnosing cancer and rare diseases, it can provide companies around the globe with agricultural solutions, and it can even aid in the fight against animal extinction, according to Dr. Carolyn Hogg and Professor Kathy Belov, researchers from the University of Sydney.

Furthermore, despite being the leading company in the industry, the stock is still relatively cheap compared to other industry-leading businesses. Several years ago, Illumina released their newest product, the NovaSeq X, which essentially allows users of this product to get genetic results at a significantly lower price than before. This single-handedly dropped continued expenses for customers by nearly 70%. These new genetic sequencers have orders four times higher than Illumina’s sequencers released in the previous year. As we continue moving further into this new year, we believe these factors and the economy’s steady return to normalcy will accelerate Illumina’s revenue growth and push its price even higher.

We purchased Illumina (ILMN) at $204.91.